Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study

• Автори: Jassada Buaboonnam (Автор), Supattra Rungmaitree (Автор), Nuntawan Piyaphanee (Автор), Sirirat Charuvanij (Автор), Onsiri Pitisuttithum (Автор), Katherine Copeland (Автор), Chatkamol Pheerapanyawaranun (Автор), Laddawan Jansarikit (Автор), Suvimol Niyomnaitham (Автор), Kulkanya Chokephaibulkit (Автор)
• Формат: Книга
• Опубліковано: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

We evaluated the immunogenicity of 300 mg Tixagevimab-Cilgavimab in immunocompromised children and adolescents who weighed 20 to >40 kg. Six to 18-year-old participants were divided into two groups by body weight and received 300 mg (20 to <40 kg) and 600 mg (≥40 kg) Tixagevimab-Cilgavimab, re...